Abstract:Psoriasis vulgaris, a chronic inflammatory skin disorder, is the result of immune mediated processes, genetic background and environmental factors. Prolactin and the vascular endothelial growth factor seem to play a key role in psoriasis pathogenesis regarding hyperproliferation of epidermal keratinocytes and dermal vascular ectasia. The aim of the study was to investigate the expression of tumor necrosis factor-α (TNF-α), vascular endothelial growth factor receptor 2 (VEGFR2) and prolactin receptor (PRLR) in psoriatic skin by immunohistochemical analysis and to evaluate the correlation with disease severity. Two skin biopsies, psoriatic lesion and perilesional skin, obtained by punch biopsy from 19 nontreated psoriasis patients were examined in hematoxylin and eosin staining and immunohistochemistry (IHC) for TNF-α, VEGFR2 and PRLR. The indirect IHC reaction was carried out automatically and visualized by 3,3-diaminobenzidine (DAB) technique. The average number of DAB-positive cells and the intensity of cell staining were quantified on a predefined scale. The results show a significant difference in the quantity and distribution of TNF-α positive cells in the two sample groups. In psoriatic plaque skin, an increased expression of TNF-α was found in the perivascular dermis and epidermic keratinocytes. In perilesional skin the immunostaining was predominant in the basal layer keratinocytes, while in psoriatic plaque, all the layers were positively marked, with stronger expression at the base. A statistically significant difference was found between the intensity of the immunostaining in the two types of tissue. Positive cells for VEGFR2 and PRL were identified in the basal layer keratinocyte cells (VEGFR2), sweat glands and hair outer shaft sheath (PRLR), without significant differences between the two types of samples. Our findings confirm the importance of TNF-α in psoriasis pathogenesis and a positive correlation with lesions severity. No significant differences were found for VEGFR2 and PRLR, but additional studies are necessary to establish their role.

Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out

Immunohistochemical Study of Vascular Endothelium Adhesion Molecules in Psoriatic and Non-psoriatic Skin

Altered morphology and distribution of cellular junction proteins in non-lesional psoriatic epidermis: an insight into disease severity

Differential Regulation of Integrin Alpha 5 and Beta 4 in Normal and Psoriatic Epidermal Keratinocytes

Liver tumor promoting effect of etofenprox in rats and its possible mechanism of action.

Analysis of Epithelial–mesenchymal Transition Markers in Psoriatic Epidermal Keratinocytes

Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis

Increased presence and differential molecular imprinting of transit amplifying cells in psoriasis

Dermal distribution of hyaluronan in psoriatic arthritis; coexistence of CD44, MMP3 and MMP9

[PETROLEUM POISONING IN CHILDREN WITH SPECIAL REFERENCE TO LUNG CHANGES].

A cloned H-2 class I gene from a tw32-derived recombinant t haplotype identified as functional H-2Kq gene.

Modulation of Toll-like receptors in psoriatic patients during therapy with adalimumab

Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: A pilot study

Populating Ancient Pompeii with Crowds of Virtual Romans

Subclinical atherogenesis in patients with mild psoriasis: A role for IL-6?

Addiction is Not a Brain Disease (and it Matters)

Cardiovascular dysfunction in sepsis at the dawn of emerging mediators.

Increased synovial immunohistochemistry reactivity of TGF-β1 in erosive peripheral psoriatic arthritis

3D skin model to investigate the early epidermal morphological psoriatic features

Stratum corneum levels of calprotectin proteins S100A8/A9 correlate with disease activity in psoriasis patients

BPMN to BPEL case study solution in V IATRA 2